D
Daniel W. Thomson
Researcher at Garvan Institute of Medical Research
Publications - 4
Citations - 1944
Daniel W. Thomson is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 1439 citations.
Papers
More filters
Journal ArticleDOI
Endogenous microRNA sponges: evidence and controversy.
TL;DR: The evidence for and against the ceRNA hypothesis are critically evaluated to assess the impact of endogenous miRNA-sponge interactions and to propose an alternative function for messenger RNAs.
Journal ArticleDOI
lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs
Xiu Cheng Quek,Daniel W. Thomson,Jesper L.V. Maag,Jesper L.V. Maag,Nenad Bartonicek,Bethany Signal,Michael B. Clark,Brian S. Gloss,Marcel E. Dinger,Marcel E. Dinger +9 more
TL;DR: The lncRNAdb database as discussed by the authors provides users with a comprehensive, manually curated reference database of 287 eukaryotic long noncoding RNA (lncRNA) genes that have been described independently in the scientific literature.
Journal ArticleDOI
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Naranie Shanmuganathan,Carol Wadham,Nur Hezrin Shahrin,Jinghua Feng,Daniel W. Thomson,Paul P. Wang,Verity A Saunders,Chung H. Kok,Rob King,Rosalie Kenyon,Ming-Hwai Lin,Ilaria S. Pagani,David L. Ross,Agnes S. M. Yong,Andrew Grigg,Anthony K. Mills,Anthony P. Schwarer,Jodi Braley,Haley Altamura,David T Yeung,Hamish S. Scott,Andreas Schibler,Timothy P. Hughes,Susan Branford +23 more
TL;DR: In this article , the authors evaluated the impact of additional genetic abnormalities (AGAs) at diagnosis of chronic phase (CP)-CML in a consecutive imatinib-treated cohort of 210 patients enrolled in the TIDEL-II trial.
Journal ArticleDOI
RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia.
Naranie Shanmuganathan,Carol Wadham,Daniel W. Thomson,Nur Hezrin Shahrin,Chloé Vignaud,Vanessa Obourn,Shalini Chaturvedi,Feng Yang,Jinghua Feng,Verity A Saunders,Chung H. Kok,David T Yeung,Rob King,Rosalie Kenyon,M Lin,Paul P. Wang,Hamish S. Scott,Timothy P. Hughes,Andreas Schibler,Susan Branford +19 more
TL;DR: In this paper , the authors proposed a method to detect mutations in 130 genes relevant for myeloid and lymphoid leukemia using a single cost-effective hybridization capture next-generation sequencing method using total RNA.